Triple Analysis: Breast Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Language: English
- Published: March 2013
- Your are here:
- Home
- Categories
- Pharmaceuticals and Healthcare
- Pharmaceuticals
- Oncology
- Breast Cancer
Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies
Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies
- Published: November 2012
- 7056 pages
- Bioseeker
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Breast Cancer
The breast cancer drug report part comprises defined and up to date development strategies for 470 drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others
Part II: Protein Kinase Inhibitors
The protein
READ MORE >
Key Topics Covered:
Part I: Breast Cancer
5.1 The Scope of this Report 32
6 Consider the Therapeutic Target Among Breast Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (234 Drug Targets) 36-522
7 Emerging New Products to Establ
| Format | Properties | |
|---|---|---|
| Electronic (PDF) | The report will be emailed to you. The report is sent in PDF format. | This is a single user license, allowing one specific user access to the product. |
| Site License | The report will be emailed to you. The report is sent in PDF format. | This is a site license, allowing all users within a given geographical location of your organisation access to the product. |
| Enterprisewide | The report will be emailed to you. The report is sent in PDF format. | This is an enterprise license, allowing all employees within your organisation access to the product. |
Note: Product cover images may vary from those shown
RELATED PRODUCTS
-
FROM
-
Triple Analysis: Colorectal Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Language: English
- Published: March 2013
FROM -
Triple Analysis: Leukemia, Cancer Vaccines and Protein Kinase Inhibitors
- Language: English
- Published: March 2013
FROM -
Triple Analysis: Lung Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Language: English
- Published: March 2013
FROM -
Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Language: English
- Published: March 2013
FROM -
Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Language: English
- Published: March 2013
FROM -
Triple Analysis: Apoptosis, Cancer Vaccines and Protein Kinase Inhibitors
- Language: English
- Published: March 2013
FROM -
Triple Analysis: Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors
- Language: English
- Published: March 2013
FROM -
Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Antibodies
- Language: English
- Published: March 2013
FROM -
Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Peptides
- Language: English
- Published: March 2013
FROM
